TriangleHEALTH PROFESSIONAL · SOURCE READING
Allogeneic SCT
Source: Chronic Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 13, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of Accelerated-Phase CML / Treatment Options for Accelerated-Phase CML
Induction of remission using a TKI and consideration of an allogeneic SCT for patients with poor responses, when feasible, is a standard approach for patients with accelerated-phase CML.[2]
Source links and citations
Evidence (imatinib vs. allogeneic SCT):
A cohort study of 132 patients with accelerated-phase CML compared imatinib with allogeneic SCT as first-line therapy, with a median follow-up of 32 months.[2][Level of evidence C1]
Source links and citations
A cohort study of 132 patients with accelerated-phase CML compared imatinib with allogeneic SCT as first-line therapy, with a median follow-up of 32 months.[2][Level of evidence C1]
The overall survival rate was improved using allogeneic SCT for the Sokal high-risk patients (100% vs. 17.7%; P = .008).
A cohort study of 132 patients with accelerated-phase CML compared imatinib with allogeneic SCT as first-line therapy, with a median follow-up of 32 months.[2][Level of evidence C1]
For Sokal low- and intermediate-risk patients, there were no survival differences between the two first-line approaches.
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice